• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form PX14A6G filed by Elevance Health Inc.

    4/7/26 2:58:31 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email
    PX14A6G 1 b47261px14a6g.htm

     

    Notice of Exempt Solicitation Pursuant to Rule 14a-6(g)

     

    Name of the Registrant: Elevance Health, Inc.

     

    Name of person relying on exemption: Trillium Asset Management, LLC

     

    Address of person relying on exemption: One Congress Street, Suite 3101, Boston, MA 02114

     

    Written materials required to be submitted pursuant to Rule 14a-6(g)(1):

     

    Letter to Elevance Health shareholders sent on April 7, 2026 in support of Item #4.

     

     

    This is NOT a solicitation of authority to vote your proxy.

    Please DO NOT send us your proxy card as it will not be accepted.

     

       
     

     

    April 7, 2026

     

    Dear Shareholders of Elevance Health, Inc.:

     

    We write to urge you to vote FOR Item #4, Trillium’s shareholder proposal at Elevance Health, Inc. (“Elevance” or “the Company”) which requests that the Company’s Board commission an independent study evaluating the impact of adopting a policy that would prohibit corporate contributions to partisan 527 political organizations.

     

    This is a targeted, reasonable request. Importantly, the proposal does not ask Elevance to change its political spending policy currently, to stop making political contributions, or to disengage from the public policy process. Instead, it seeks a responsible, modest step: an independent assessment to help shareholders understand whether this specific category of spending from the company’s treasury (not the political action committee) serves the long-term interests of the Company and its shareholders.

     

    Partisan 527s present distinctive governance and risk-management challenges because they aggregate funds and distribute support across a wide array of partisan candidates and political efforts. Examples of 527s include the Republican Attorneys General Association, the Democratic Governors Associations, the Republican State Leadership Committee, or the Democratic Legislative Campaign Committee. As a result, Elevance does not control which candidates and causes ultimately benefit from its corporate dollars being given to 527s.i

     

    This structure invites heightened risk that corporate funds may indirectly support positions or candidates that conflict with Elevance’s publicly stated commitments, including efforts related to health equity, Medicaid access, and climate goals. It also adds to the risk of alienating key stakeholders – employees, customers, and shareholders – who, like the public at large, hold diverse political views.

     

    Importantly, Elevance has not demonstrated that its contributions to partisan 527 organizations provide measurable value to the Company or its shareholders. In 2024, Elevance spent over $2.1million – nearly half of its total political contributions – on these partisan political organizations.ii In addition, a report by the Center for Political Accountability highlights substantial contributions over time, including to $1.3 million to the Republican Attorneys General Association and $9.7 million to the Republican Governors Association, since 2010.iii This concern is also true when it comes to organizations associated with the Democrats. In the Company’s most recent political contributions report which covers the first half of 2025, it reports that it spent $1.6 million on partisan 527 organizations.iv

     

     

    This is NOT a solicitation of authority to vote your proxy.

    Please DO NOT send us your proxy card as it will not be accepted.

     

       
     

     

    Yet the Company does not appear to provide shareholders with evidence that such contributions improve access to policymakers, advance specific policy outcomes, or deliver tangible benefits that justify their scale.

     

    In its opposition statement the Company emphasizes its existing policies, governance processes, and disclosures regarding political spending as reasons to vote against the proposal. While oversight and transparency are important, what is more important for shareholders to consider is that this argument does not answer the central question shareholders are entitled to ask: Do corporate treasury contributions to partisan 527 organizations deliver demonstrable benefits to Elevance and its shareholders - or is the benefit unproven?

     

    Governance processes tell shareholders how decisions are made. However, they do not establish whether those decisions produce value, nor whether they create unnecessary reputational, operational, or stakeholder-alignment risks. The Company’s assertions that restricting 527 contributions would hinder its advocacy efforts are just assumptions unless supported by data – data that shareholders do not currently have and that this proposal seeks to develop through an independent study.

     

    Given the magnitude of these contributions and the absence of demonstrated return on investment, an independent study is a reasonable and prudent next step. It would provide objective information to help the Board and shareholders assess whether this spending practice aligns with Elevance’s long-term strategy and risk profile—and whether a policy change would strengthen, rather than impair, the Company’s advocacy effectiveness and stakeholder trust.

     

    If you have any questions or need additional information, please contact Jonas Kron at jkron@trilliuminvest.com.

     

    For these reasons, we urge you to vote FOR Item #4 at the upcoming annual meeting.

     

    Respectfully,

     

    Trillium Asset Management

     

     

    This is NOT a solicitation of authority to vote your proxy.

    Please DO NOT send us your proxy card as it will not be accepted.

     

       
     

     

    IMPORTANT NOTICE: The views expressed are those of the authors as of the date referenced and are subject to change at any time based on market or other conditions. These views are not intended to be a forecast of future events or a guarantee of future results. These views may not be relied upon as investment advice. The information provided in this material should not be considered a recommendation to buy or sell any of the securities mentioned. It should not be assumed that investments in such securities have been or will be profitable. To the extent specific securities are mentioned, they have been selected by the authors on an objective basis to illustrate views expressed in the commentary and do not represent all of the securities purchased, sold or recommended for advisory clients. The information contained herein has been prepared from sources believed reliable but is not guaranteed by us as to its timeliness or accuracy, and is not a complete summary or statement of all available data. This piece is for informational purposes and should not be construed as a research report.

     

     

     

    i https://www.politicalaccountability.net/wp-content/uploads/2024/08/Corporate-Underwriters-Where-the-Rubber-Hits-the-Road.pdf

    iihttps://s202.q4cdn.com/665319960/files/doc_governance/2025/2024_Elevance_Health_Political_Giving_Report.pdf

    iii https://www.politicalaccountability.net/wp-content/uploads/2024/08/Corporate-Underwriters-Where-the-Rubber-Hits-the-Road.pdf

    iv https://s202.q4cdn.com/665319960/files/doc_downloads/political-contributions/2025-Elevance-Health-Mid-Year-Political-Contributions-Report.pdf

     

     

    This is NOT a solicitation of authority to vote your proxy.

    Please DO NOT send us your proxy card as it will not be accepted.

     

     

     

     

    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    5/20/2026$498.00Hold → Buy
    Deutsche Bank
    4/29/2026$435.00Neutral → Buy
    BofA Securities
    4/8/2026$345.00In-line
    Evercore ISI
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    More analyst ratings

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act

    Research finds arbitration awards for certain planned procedures are often far higher than typical in-network payment rates The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop is increasingly contributing to higher out-of-network costs. The study examined more than 7,300 paym

    6/25/26 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    SEC Filings

    View All

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 11:27:18 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    7/15/26 6:01:33 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Elevance Health Inc.

    11-K - Elevance Health, Inc. (0001156039) (Filer)

    6/17/26 1:58:21 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 3:04:55 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/17/26 1:50:44 PM ET
    $ELV
    Medical Specialities
    Health Care

    CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    6/15/26 4:10:45 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Elevance Health from Hold to Buy and set a new price target of $498.00

    5/20/26 8:03:29 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $435.00

    4/29/26 8:00:15 AM ET
    $ELV
    Medical Specialities
    Health Care

    Evercore ISI initiated coverage on Elevance Health with a new price target

    Evercore ISI initiated coverage of Elevance Health with a rating of In-line and set a new price target of $345.00

    4/8/26 8:36:16 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

    2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025 2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions FY 2026 operating cash flow guidance raised to at least $6.0 billion Elevance Health, In

    7/15/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

    Elevance Health (NYSE:ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    7/6/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance

    1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 1Q 2026 diluted EPS1 of $8.00; adjusted diluted EPS2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income FY 2026 diluted EPS1 guidance to be at least $19.85, including the Company's estimate of the financial impact for the CMS matter FY 2026 adjusted diluted EPS2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter Returned $1.5 billion of capital to shareholders in

    4/22/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care